Frozen Leukopaks are collected from IRB consented healthy donors at our FDA-registered Stem Cell Collection Center. Using the Spectra Optia® Apheresis System, cell-rich peripheral blood mononuclear cells (PBMCs) are extracted using a continuous flow centrifugation system directly into a sterile collection bag containing the anticoagulant ACD-A. Besides the PBMCs, which consist of lymphocytes and monocytes, each Leukopak will also contain minimal amounts of granulocytes and red blood cells.
The following are mean percentages of cell populations for a single donor Leukopak prior to cryopreservation:
- T cells – 55%
- Monocytes – 27%
- B cells – 9%
- NK cells – 8%
- CD34+ stem cells – 0.1%
- Granulocytes – 2.4%
We do not guarantee the percentage of cell populations in a Leukopak, as they can vary from donor to donor.
Once collected, Leukopaks are quickly frozen in a medium containing the cryoprotective agent CryoStorTM (10% DMSO) using a controlled rate freezer to ensure maximum viability.
Total nucleated cell (TNC) counts and viability testing are performed prior to cryopreservation. For optimal cell recovery and viability, we recommend following our Thawing Protocol found under the Technical Resources tab. Deviations from this protocol can compromise viability and cell recovery.
For global shipments, we highly recommend shipping Frozen Leukopaks in an LN2 cryoshipper to maintain proper temperatures for the duration of the transit time. Upon arrival, Frozen Leukopaks should be stored in the vapor phase of liquid nitrogen or thawed immediately for use.
Design the right Leukopak for your research needs. View our custom orders to see what options we have available.
|Cell and Tissue Source|
Product Information Sheet
Human Peripheral Blood Leukopak, Frozen – Product Information Sheet
Certificate of Analysis
Human Peripheral Blood Leukopak, Frozen – Sample CoA
Material Safety Data Sheet
Human Peripheral Blood Leukopak, Frozen – MSDS